WALTHAM, Mass. – December 17, 2014 – X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, today announced it has licensed a second drug discovery program to Bayer Pharma AG pursuant to the multi-target collaboration the companies established in July 2012.

WALTHAM, MA – December 11th, 2014 – X-Chem, Inc., a biotechnology company focused on the generation of novel small molecule therapeutics using its proprietary DNA-encoded library platform, today announced the initiation of a drug discovery collaboration with Alexion (Nasdaq: ALXN), a global leader in the development and commercialization of life-transforming therapies for patients with severe […]

WILMINGTON, N.C. and WALTHAM, Mass.– September 25, 2014 – Pharmaceutical Product Development, LLC (PPD) and X-Chem, Inc. announced today that PPD has exercised its option to acquire the remaining minority ownership interest of X-Chem, Inc.

WALTHAM, Mass. – June 11, 2014 – X-Chem, Inc., a privately held biotechnology company applying its cutting-edge lead discovery capabilities to the generation of novel small molecule therapeutics, today announced a multi-target collaboration with Pfizer Inc. The collaboration is focused on the potential development of several programs for the treatment of inflammatory and orphan diseases.

WALTHAM, Mass. – February 13, 2014 – X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, today announced it has achieved a success milestone with Bayer Pharma AG in the multi-target collaboration the companies established in July 2012.

WALTHAM, MA, USA – February 4, 2014 – X-Chem, Inc., a privately held biotechnology company focused on applying its powerful product engine to the generation of novel small molecule therapeutics, today announced that the company has created the first biotech-owned screening library of DNA-encoded small molecules to ever surpass 100 billion compounds.

WALTHAM, Mass. – January 10, 2014 – X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, today announced it has entered into a partnership with PsyBrain, Inc. to discover new drugs for treating psychiatric illnesses.

WALTHAM, Mass. – October 3, 2013 – X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, today announced it has entered into an expanded global drug discovery collaboration with AstraZeneca across all of the pharmaceutical company’s therapeutic areas and multiple target […]

WALTHAM, Mass. – September 24, 2013 – X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, today announced it has achieved several milestones leading to the licensing of three drug discovery programs by AstraZeneca, in the context of a collaboration the […]

WALTHAM, MA, USA – (July 1, 2010) – X-Chem, Inc. today announced the signing of a multi-year collaborative agreement with Roche to apply X-Chem’s proprietary platform to the rapid discovery of drug candidates against several of Roche’s high-value therapeutic targets.